Amgen vs. Vertex Pharmaceuticals: Comparing Healthcare Giants for Portfolio Growth

When looking for stability in the healthcare sector, everyday investors frequently weigh the contrasting business models of Amgen and Vertex Pharmaceuticals. Amgen features a broad portfolio spanning oncology, inflammation, and rare diseases, resulting in revenue of approximately $38.9 billion for the 12 months ended September 30, 2026. This reflects an 8.3% increase from the prior period, alongside net income of nearly $9.4 billion. However, the firm relies heavily on three major distributors, which accounted for roughly 77% of its revenues in 2025.

Conversely, Vertex Pharmaceuticals operates as a specialized biotech leader with a dominant position in cystic fibrosis treatments, recently launching the once-daily triple-combination regimen Alyftrek. The company expanded into sickle cell disease through the joint development of Casgevy with CRISPR Therapeutics. For the 12 months ended September 30, 2026, Vertex posted revenue of about $13.0 billion, marking 10.8% growth, with net income reaching around $4.0 billion.

Financial metrics illustrate different approaches to capital management between the two industry players. Amgen utilizes significant borrowed capital, holding a debt-to-equity ratio of roughly 6.3x as of December 2025, alongside a free cash flow of about $8.1 billion for the fiscal year. In contrast, Vertex maintains a conservative debt-to-equity ratio of approximately 0.1x and generated nearly $3.2 billion in free cash flow for the same period. While Amgen presents a more affordable valuation with a lower Forward P/E and P/S ratio, both companies manage distinct operational and regulatory challenges.